COCLI-2021: Combating Overdose through Community-Level Intervention
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Office of National Drug Control Policy notices from 2021.
Office of National Drug Control Policy offered grants of up to $3.0 million (at least $3.0 million) to nonprofits and colleges and universities. It expected to make one award. Applications closed on August 13, 2021.
From the official notice on Grants.gov, last changed August 5, 2021. Checked November 7, 2026.
- Award ceiling$3.0 million
- Award floor$3.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| CCL-CCL-23-001 | July 31, 2023 | Closed August 31, 2023 | Closed |
| COCLI-2022 | June 23, 2022 | Closed July 22, 2022 | Closed |
Key dates
| Posted | August 5, 2021 |
|---|---|
| Deadline | August 13, 2021 |
| Archived by Grants.gov | September 12, 2021 |
Who can apply
This opportunity was open to nonprofits and colleges and universities.
- Public and State controlled institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Is this a realistic fit?
- Past Research and Data Analysis awards averaged $915,665; this notice allows up to $3.0 million per award.
- Most of the program's money (65% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
Overview The overdoses continue throughout the United States, claiming an alarming number of lives each year. Drug overdose is the leading cause of injury death in the United States, surpassing motor vehicle crashes since 2009.1 According to provisional data released by the Centers for Disease Control and Prevention (CDC), reported drug overdoses accounted for over 92,000 U.S. deaths in 2020, which is nearly a 30 percent increase from 2019. The new data release revealed other grim realities this past year: the most drug overdose deaths in a year; the most deaths from opioid overdoses; the most overdose deaths from stimulants like methamphetamine; the most deaths from the deadly class of synthetic opioids known as fentanyls. Moreover, the reported number of opioid-involved drug overdose deaths in the United States for the 12-month period ending in December 2020 (68,821) increased from 50,178 in the previous year. The drug overdose epidemic has been exacerbated during the COVID-19 pandemic, presenting new challenges to public health and public safety officials, medical professionals, local communities, and other stakeholders invested in curbing rates of accidental death. Preparing regional and community leaders to respond effectively to the public health emergency that is today’s drug overdose crisis (and be prepared to take on that crisis as it evolves during the COVID-19 pandemic) is essential for achieving the shared goal of preventing fatal overdose and saving lives. ONDCP expects to award one Federal cooperative agreement under the Combating Overdose through Community-Level Intervention Initiative (COCLI) for a 1-year period, beginning approximately September 2021. The successful non-Federal entity (NFE) will conduct research activities that entail implementing and evaluating community-based efforts to fight the overdose epidemic. These activities will be focused on the regions of the United States with some of the highest rates of fatal and non-fatal overdoses and will work to coordinate the often decentralized state and local efforts to assess and respond to overdoses. Efforts will also support and promote the partnership of law enforcement and public health agencies, as coordination and collaboration between these two groups is proving critical to addressing this epidemic. Efforts will also align with and be informed by related projects currently being conducted by ONDCP and CDC, and both agencies will work closely with the successful NFE.
Who has won Research and Data Analysis grants before
From fiscal 2021 to 2025, Research and Data Analysis (95.007) awarded $9.2 million across 10 grant awards, an average of $915,665 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Baltimore | Maryland | 2 | $5.9 million |
| National Association of County and City Health Officials | District of Columbia | 1 | $1.2 million |
| National Foundation for the Centers for Disease Control & Prevention, Inc. | Georgia | 1 | $700,000 |
| University of Maryland, College Park | Maryland | 3 | $574,998 |
| American College of Medical Toxicology, Inc. | Arizona | 1 | $400,000 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is COCLI-2021 still open?
No. It closed on August 13, 2021.
Who can apply for Combating Overdose through Community-Level Intervention?
Office of National Drug Control Policy accepted applications from nonprofits and colleges and universities.
What is the deadline for Combating Overdose through Community-Level Intervention?
Closed August 13, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $3.0 million each.
Who has won Research and Data Analysis grants before?
The largest recipients over five fiscal years were University of Baltimore, National Association of County and City Health Officials, National Foundation for the Centers for Disease Control & Prevention, Inc. The program made 10 awards worth $9.2 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)